XML 114 R75.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions (Tables)
12 Months Ended
Dec. 31, 2022
Disclosure of transactions between related parties [abstract]  
Summary of Nature of Related Party Relationship
CompanyRelationship
Nanjing GenScript Biotech Co., Ltd. (formerly named as Nanjing Jinsirui Biotechnology Co., Ltd.)Company controlled by the ultimate holding company
Jiangsu GenScript Biotech Co., Ltd.Company controlled by the ultimate holding company
Genscript USA IncorporatedCompany controlled by the ultimate holding company
Genscript USA Holdings IncCompany controlled by the ultimate holding company
Genscript Biotech (Netherlands) B.V.Company controlled by the ultimate holding company
Nanjing Probio Biotech Co., Ltd.Company controlled by the ultimate holding company
Jiangsu GenScript Probio Biotech Co., Ltd.Company controlled by the ultimate holding company
Genscript NetherlandsCompany controlled by the ultimate holding company
Genscript Biotech Corporation (“GenScript”)Company controlled by the ultimate holding company
Genscript Probio USA Inc.Company controlled by the ultimate holding company
Summary of Transactions with Related Parties In addition to the transactions detailed elsewhere in the consolidated financial statements, the Company had the following transactions with related parties during the year:
(i)Licensing of patents to related parties:
202220212020
US$’000US$’000US$’000
Nanjing Probio Biotech Co., Ltd.— 3,019 — 
The sale was generated from an exclusive licensing of certain patents to Nanjing Probio Biotech Co., Ltd and its affiliates.
(ii)Sales-based royalties from related parties:
202220212020
US$’000US$’000US$’000
Nanjing Probio Biotech Co., Ltd.328 405 — 
The sale was generated from sales-based royalties related to the exclusive licensing of certain patents to Nanjing Probio Biotech Co., Ltd and its affiliates.
(iii)Purchases from related parties:
202220212020
US$’000US$’000US$’000
Nanjing GenScript Biotech Co., Ltd.6,174 9,615 4,162 
Jiangsu GenScript Probio Biotech Co., Ltd1,306 334 — 
Genscript USA Incorporated1,028 786 424 
Genscript USA Holdings Inc380 — — 
Nanjing Probio Biotech Co., Ltd.237 21 — 
Jiangsu GenScript Biotech Co., Ltd51 146 41 
GenScript Probio USA Inc.— — 
Genscript Netherlands— 
Total 9,189 10,908 4,627 
Compensation fee for termination of service agreement:
202220212020
US$’000US$’000US$’000
Jiangsu GenScript Biotech Co., Ltd.— 2,666 — 
Financing from follow-on public offering, net of issuance cost
202220212020
US$’000US$’000US$’000
Genscript Biotech Corporation— 84,600 — 
Disclosure of Outstanding Balances with Related Parties Explanatory
The Company had the following significant balances with its related parties at the end of the year:
(i)Due from related parties
December 31,
2022
December 31,
2021
US$’000US$’000
Trade receivables
Nanjing Probio Biotech Co., Ltd.90 409 
December 31,
2022
December 31,
2021
US$’000US$’000
Other receivables
Nanjing GenScript Biotech Co., Ltd.321 243 
Genscript USA Incorporated16 19 
Jiangsu Genscript Biotech Co., Ltd— 
Total 340 262 
December 31,
2022
December 31,
2021
US$’000US$’000
Prepayment
Nanjing Probio Biotech Co., Ltd.251 274 
Jiangsu GenScript Probio Biotech Co., Ltd21 925 
Total272 1,199 
(ii)Due to related parties.
December 31,
2022
December 31,
2021
US$’000US$’000
Trade payables
Nanjing GenScript Biotech Co., Ltd.935 2,301 
Genscript USA Incorporated134 46 
Jiangsu GenScript Biotech Co., Ltd93 
Nanjing Probio Biotech Co., Ltd.21 22 
Total1,183 2,370 
December 31,
2022
December 31,
2021
US$’000US$’000
Other payables
Nanjing GenScript Biotech Co., Ltd.2,435 3,293 
GenScript USA Incorporated.58 50 
Jiangsu Genscript Biotech Co., Ltd— 
Jiangsu Genscript Probio Biotech Co., Ltd— 
Nanjing Probio Biotech Co., Limited— 
Genscript Netherlands— 
Total2,508 3,343 
December 31,
2022
December 31,
2021
US$’000US$’000
Lease liabilities
Genscript USA Holdings Inc427 — 
Nanjing GenScript Biotech Co., Ltd.205 286 
Total 632 286 
Summary of Compensation of Key Management Personnel Compensation of key management personnel of the Company:
202220212020
US$’000US$’000US$’000
Equity-settled share-based compensation expense3,582 2,907 529 
Short-term employee benefits2,170 1,942 1,733 
Termination payment— — 774 
Total 5,752 4,849 3,036